At 2.8% CAGR, Middle East & Africa Epilepsy Market is Projected to be Worth US$ 568.00 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa epilepsy market was valued at US$ 456.34 million in 2022 and is expected to reach US$ 568.00 million by 2030, registering a CAGR of 2.8% from 2022 to 2030. Rising prevalence of epilepsy and surge in awareness programs conducted by organizations are among the critical factors attributed to drive the Middle East & Africa epilepsy market growth.

Epilepsy, also termed a seizure disorder, is a chronic disease of the brain. It is characterized by recurrent seizures, which are brief episodes of involuntary movement of a part of the body or the entire body. Seizures can alter sensations, behaviors, awareness, and muscle movements. Epilepsy may occur due to a genetic disorder or an acquired brain injury, such as trauma or stroke. According to data published by the World Health Organization (WHO) in February 2023, epilepsy accounts for a significant share of the worldwide disease burden, affecting nearly 50 million people across the world. Moreover, 4-10 persons per 1,000 individuals are estimated to have active epilepsy (i.e., with the need for treatment or continuing seizures). Nearly 5 million people are diagnosed with epilepsy every year. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. This number can reach as high as 139 per 100,000 individuals in low- and middle-income countries. An upsurge in epilepsy incidence can be attributed to the higher count of road traffic injuries and birth-related injuries, and the elevated risk of endemic conditions such as neurocysticercosis or malaria. The WHO also states that approximately 70% of individuals with epilepsy can become seizure-free with the use of medications. Treatments to control epilepsy include anti-epileptic medications, special diets (in addition to anti-seizure medications), and surgery; however, anti-epileptic drug therapy is the primary treatment prescribed for most patients. Thus, the rising prevalence of epilepsy worldwide drives market growth.

On the contrary, recall of products hampers the growth of Middle East & Africa epilepsy market.

Based on type, the Middle East & Africa epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held 52.6% market share in 2022, amassing US$ 240.17 million. It is projected to garner US$ 307.29 million by 2030 to register 3.1% CAGR during 2022-2030.

In terms of route of administration, the Middle East & Africa epilepsy market is categorized into oral, parenteral, and others. The oral segment held 67.8% share of Middle East & Africa epilepsy market in 2022, amassing US$ 309.38 million. It is anticipated to garner US$ 399.79 million by 2030 to expand at 3.3% CAGR during 2022-2030.

By treatment type, the Middle East & Africa epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held 42.6% share of Middle East & Africa epilepsy market in 2022, amassing US$ 194.40 million. It is projected to garner US$ 250.37 million by 2030 to expand at 3.2% CAGR from 2022 to 2030.

Based on age group, the Middle East & Africa epilepsy market is bifurcated into adult and children. The adult segment held 79.9% share of Middle East & Africa epilepsy market in 2022, amassing US$ 364.49 million. It is predicted to garner US$ 459.12 million by 2030 to expand at 2.9% CAGR between 2022 and 2030.

In terms of distribution channel, the Middle East & Africa epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held 51.2% share of Middle East & Africa epilepsy market in 2022, amassing US$ 233.53 million. It is projected to garner US$ 281.33 million by 2030 to expand at 2.4% CAGR from 2022 to 2030.

By country, the Middle East & Africa epilepsy market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 27.7% share of Middle East & Africa epilepsy market in 2022. It was assessed at US$ 126.60 million in 2022 and is likely to hit US$ 147.87 million by 2030, registering a CAGR of 2.0% during 2022-2030.

Key players operating in the Middle East & Africa epilepsy market are Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS, among others.

• In May 2023, the biotechnology company Neuro3 Therapeutics (Neuro3), which focuses on finding and creating novel medications to treat illnesses of the central nervous system has signed an exclusive global license and option deal with Lundbeck. The agreement focuses on KCNQ2 ion channel activators, which have been clinically verified as targets for epilepsy treatment. According to clinical research, KCNQ2 channel activation may offer therapeutic alternatives for treating various neurological conditions, such as uncommon forms of epilepsy. The agreement states that Neuro3 will be in charge of developing the two clinical stage and one pre-clinical stage KCNQ2 activator program further through clinical proof-of-concept (PoC). Neuro3 will also obtain a worldwide license for intellectual property related to these products. Lundbeck and Neuro3 may choose to co-develop and co-commercialize after the PoC experiments are finished. Furthermore, Lundbeck has the ability to re-exclusively lease the rights back in specific regions.
  
  
• In October 2022, Following Pfizer Inc.'s acquisition of Biohaven Pharmaceuticals, Biohaven Pharmaceuticals declared its intention to develop treatments for neurological and neuropsychiatric conditions. The company is concentrating on BHV-7000, an investigational therapy for epilepsy that targets the Kv7 ion pathway. Phase I development of BHV-7000 is in underway for a number of indications.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com